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≥+2; P = 0.002,) and pHER2 (0 vs. ≥+1; P = 0.001) expressions were 
signiﬁcantly associated with incidence of EGFR mutation.
Conclusions: EGFR mutation was a signiﬁcant predictive biomarker 
of response to geﬁtinib. Phosphorylated EGFR protein expression is a 
potent replaceable biomarker for EGFR mutation.
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Background: EGFR mutations have been recognized as a predictor of 
favorable clinical outcomes in non-small-cell lung cancer (NSCLC) pa-
tients treated with geﬁtinib. Never-smoking status is also considered to 
be a predictive factor and may be a determinant for geﬁtinib treatment. 
We have independently reported the relationship between EGFR muta-
tions and clinical beneﬁt in NSCLC patients treated with geﬁtinib. In 
this study, we combined our data and re-analyzed the factors that would 
affect on clinical outcome in patients treated geﬁtinib. 
Methods: The EGFR mutation status restricted in exon19 deletion and 
L858R exon21 mutation was determined in 408 NSCLC patients who 
were treated with geﬁtinib using PCR-based assay. The clinical record 
including clinicopathological factors, tumor response and survival time 
were reviewed for 408 patients and correlated with EGFR status. 
Results: In the total case, tumor response was observed in 155 patients 
showed tumor response and 239 patients showed no response. Fourteen 
patients were not evaluable. Among examined factors, EGFR mutation 
was only signiﬁcant factor for tumor responsiveness (p<0.0001), pro-
longed overall (p<0.0001) and progression-free survivals (p<0.0001) 
by multivariate analysis. To analyze the impact of EGFR mutation 
and smoking on treatment outcomes with geﬁtinib, we classiﬁed our 
patients into 4 groups based on EGFR mutation and smoking status: 
(A) 104 patients with EGFR mutation and never-smoking history, (B) 
64 patients with EGFR mutation and smoking history, (C) 74 patients 
with EGFR wild-type and never smoking history, (D) 166 patients 
with EGFR wild-type and smoking history. The survival times includ-
ing overall survival and progression-free survival of each group were 
compared (Fig.1). There was no signiﬁcant difference among A and 
B groups or among C and D groups. There was signiﬁcant difference 
between A or B and C or D groups, conﬁrming that the EGFR mutation 
not smoking status is a predictor for a prolonged survival of patients 
(A vs C, p<0.0001; A vs D, p<0.0001, B vs C, p=0.0004); B vs D, 
p<0.0001). 
Conclusions: Our large-scale data indicates that EGFR mutation at 
exons 19 and 21 status is a predictive factor for favorable clinical out-
come in patients treated with geﬁtinib. 
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OX-40, also known as CD134, is a 50-kDa type-I membrane glycopro-
tein that belongs to the tumor necrosis factor (TNF) receptor superfam-
ily and serves as a T-cell co-stimulatory molecule. In vivo, deliberate 
ligation of OX40 in tumor-bearing mice induced tumor eradication, 
whereas, in some of the models, administration of agonistic OX40 
monoclonal antibody (mAb) alone was not sufﬁcient to induce tumor 
eradication. Our preliminary experiments also showed insufﬁcient 
therapeutic outcome using agonistic anti-OX40 mAb alone. Therefore, 
development of more powerful strategies is deﬁnitely required to aug-
ment immunotherapeutic effects with agonistic anti-OX40 mAb. Ioniz-
ing radiotherapy is one of the core modalities for treatment of localized 
cancer. However, radiation can cause additional immunosuppressive 
effects in the cancer host through bone marrow suppression, resulting 
in reduction of the absolute number of cells responsible for immunity 
and elevated levels of irradiated tissue-derived TGF-β and IL-10. In 
contrast, it has been shown that irradiation has a role in enhancing 
tumor immunogenicity and homing effector cells to the tumor site via 
induction of tumor apoptosis and upregulation of MHC, costimulatory, 
and adhesive molecules on tumor cells. Under these circumstances, in-
vestigators have attempted to optimize the use of irradiation in concert 
with various immunological modalities such as recombinant cytokines, 
cytokine-gene-transduced tumor or virus vaccinations, dendritic cells, 
agonistic anti-CD40 monoclonal antibody, ex vivo activated cells from 
draining lymph nodes (DLNs), adoptive transfer of antigen-speciﬁc T 
cells and peritumoral injection of CpG ologodeoxynucleotide in mouse 
experimental models. Based on the previous knowledge, we focused on 
irradiation as an immunological partner of agonistic anti-OX40 mAb 
therapy. In the present study, we attempted to elucidate the therapeutic 
effect of combining agonistic anti-OX40 mAb and irradiation in a mu-
rine lung cancer model. After intradermal transplantation of ovalbumin-
transfected LLC (LLC-OVA), C57BL/6 mice were locally irradiated 
with a single dose of 20Gy in combination with intratumoral injec-
tion of anti-OX40 mAb at 50μg on day 4 when the inoculated tumor 
reached a diameter of 7 to 9 mm. On day 8, 11 and 14, the tumor-bear-
ing mice were further treated with the same dose of anti-OX40 mAb. 
Anti-OX40 mAb in combination with radiotherapy provided greater ef-
ﬁcacy than either single treatment against well-established tumors and 
prolonged survival. In vivo depletion study suggested that therapeutic 
immunity was mainly CD8+ T cell-dependent. OX40+CD8+ T cells were 
augmented in draining lymph nodes (DLNs) obtained from irradi-
ated mice compared with those from non-irradiated mice. OVA-MHC 
tetramer+ CD8+ T cells were highly recruited in DLNs obtained from 
mice treated with anti-OX40 mAb in combination with radiotherapy, 
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and strong antigen-speciﬁc cytotoxicity was conﬁrmed by 51Cr-release 
assay. Moreover, tumor-rechallenge model indicated that this combina-
tion therapy induced durable tumor immunity. These results suggested 
that anti-OX40 mAb therapy in combination with radiotherapy may 
potentially help the management of patients with lung cancer.
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Purpose: To determine the role of HSP27 in non-small cell lung cancer 
(NSCLC) in tumor samples (expression) and in in-vitro and in-vivo 
models (overexpression/ suppression).
Methods: Tumor tissue microarrays (TMA) were stained for HSP27 
and Phospho-HSP27 (IHC) and results correlated with outcome. 
Expression in metastases was compared with the respective matched 
primary tumors. HSP27 was overexpressed using lentivirus transfected 
A549 cells and compared with control sequence transfected A549. 
Cells were studied a) in-vivo for tumor growth, b) in-vitro for motility 
by time lapse microscopy. HSP27 was suppressed with speciﬁc siRNA 
(in-vitro) and HSP27 antisense (OGX-427; in-vitro and in-vivo). Nor-
mal human bronchial epithelial cells (NHBE) were used as controls (in-
vitro). Cell cycle analysis was performed. Wortmannin and LY290042 
were used to inhibit PI3K. Gene expression proﬁle of HSP27 transfect-
ed A549 cells was compared to sham transfected A549 cells.
Results: HSP27/ Phospo-HSP27 were overexpressed in 65%/ 61% of 
tumor tissues. HSP27 expression was signiﬁcantly higher in matched 
metastases in comparison to primary tumors (p<0.0001). HSP27 was 
overexpressed in 92% of Stage IIIB/IV and 65% of Stages I-IIIA 
(p=0.048) tumors. HSP27 expression only showed a trend towards 
negative prognosis in squamous cell histology, but was not prognostic 
for NSCLC overall. HSP27 overexpressing cells showed signiﬁcantly 
increased tumor growth in-vivo and cell motility in-vitro in comparison 
to control transfected cells. HSP27 suppression with speciﬁc siRNA 
and OGX-427 antisense lead to growth inhibition and tumor cell death. 
Cell cycle analysis showed induction of apoptosis. There was no toxic 
effect on NHBE cells and mice. OGX-427 treatment in-vivo lead to a 
dramatic decrease in tumor growth in comparison to control antisense 
treated animals (p<0.01). In addition OGX-427 treatment signiﬁcantly 
decreased cell motility/ migration and membrane rufﬂing. PI3K inhibi-
tion with both Wortmannin and LY290042 abrogated the pro-motility 
effects of HSP27 overexpression. Gene expression proﬁles differed 
signiﬁcantly between the HSP27 and sham transfected cell lines.
Conclusions: HSP27 is a promising novel target in NSCLC with a role 
in tumor growth and motility. HSP27 induced cell motility is PI3K de-
pendent. Increased expression in metastases suggests a role of HSP27 
in the metastatic process in patients. HSP27 inhibition is feasible both 
in-vitro and in-vivo and leads to a marked decreased in tumor growth, 
induction of apoptosis, and abrogation of cell motility/ membrane ruf-
ﬂing. OGX-427 (HSP27 antisense) is promising for further studies and 
clinical development in NSCLC (a phase I study will start in late 2007).
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Background: Despite broad co-expression of EGFR and EGF family 
ligands in NSCLC, only a subset of patients respond to EGFR inhibi-
tors. Mechanisms underlying primary resistance to EGFR inhibitors 
are poorly deﬁned. Based on the observed presence of multiple growth 
loops in both SCLC and NSCLC we proposed that resistance of 
NSCLC to EGFR inhibitors derives from co-expression of additional 
receptors that function as sensitive autocrine loops. When Affyme-
trix GeneChip data from a panel of 31 NSCLC lines was mined for 
co-expression of additional growth factors and their cognate receptors, 
frequent co-expression of the FGF2 and its receptors FGFR1 and/or 2 
was found. 
Methods: Quantitative RT- PCR(QPCR) conﬁrmed FGF2 and FGFR 
mRNA expression. Secretion of FGF2 and the EGFR ligand TGF-
aplha was assessed by ELISA. FGFR1 & 2 protein expression was 
conﬁrmed by western blot. PCR analysis of FGFR1 & 2 splice variants 
conﬁrmed expression of the FGFR1c and FGFR2c isoforms which bind 
FGF2. FGF2 receptor stimulated ERK phophorylation was analyzed by 
western blot. The role of FGF2 and FGFR1 in proliferation/anchorage 
independent growth was evaluated through shRNA FGF2 silencing, 
expression of dominant negative FGFR1 and RO4383596, a pharma-
cological small molecule inhibitor of FGFRs, VEGFRs and PDGFRs. 
Lack of VEGFR and PDGFR expression was conﬁrmed. Combination 
effects of RO4383596 plus geﬁtinib on proliferation were evaluated by 
MTS assay, on anchorage-independent growth using soft agar colony 
formation and on ERK-MAP kinase signaling by western blot. 
Results: QPCR completed on 17 lines conﬁrmed FGF2 and FGFR1 & 
2 mRNA expression predicted from Affymetrix data. ELISA analysis 
of conditioned medium from 9 lines demonstrated secreted FGF2 
protein alone or in combination with TGFα in geﬁtinib resistant lines. 
Geﬁtinib sensitive lines were TGF-alpha positive but rarely positive for 
FGF2 secretion. Western blot conﬁrmed FGFR1 & 2 mRNA expression 
patterns. Eleven of 17 lines examined expressed the FGFR1c and/or 
FGFRc isoforms. Also, ERK phophorylation by FGF2 stimulation was 
limited to lines expressing FGFR1c or FGFR2c. shRNA reduction of 
secreted FGF2 evaluated in one line inhibited proliferation and anchor-
age-independent growth compared to empty vector as did expression of 
a dominant-negative FGFR1. RO4383596 inhibited FGF2 but not EGF 
stimulated ERK activation. Proliferation and anchorage-independent 
growth was inhibited by RO4383596 in lines that secreted FGF2 alone. 
No additive beneﬁts were observed by geﬁtinib addition. RO4383596 
induced little or no growth inhibition in geﬁtinib resistant lines that se-
creted both FGF2 and TGF-alpha. Additive growth inhibition was fol-
lowed by addition of geﬁtinib. In TGF-alpha alone positive cell lines, 
RO4383596 alone and the combination had no beneﬁt. In geﬁtinib 
sensitive lines that secreted FGF2 and TGF-alpha each agent alone 
reduced growth and the combination completely inhibited growth. 
Conclusions: We provide evidence for FGF2 signaling pathways in 
NSCLC which may contribute to primary geiﬁtinib resistance. Thera-
peutic strategies of combining approved EGFR inhibitors with novel 
FGFR inhibitors may enhance tumor growth inhibition in NSCLC 
patients. 
